Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting.

Autor: Miyahira AK; Science Department, Prostate Cancer Foundation, Santa Monica, California, USA., Kamran SC; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Jamaspishvili T; Department of Pathology and Laboratory Medicine, SUNY Upstate Medical University, Syracuse, New York, USA., Marshall CH; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Maxwell KN; Department of Medicine-Hematology/Oncology and Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Medicine Service, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA., Parolia A; Department of Pathology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA., Zorko NA; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.; University of Minnesota Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA., Pienta KJ; The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Soule HR; Science Department, Prostate Cancer Foundation, Santa Monica, California, USA.
Jazyk: angličtina
Zdroj: The Prostate [Prostate] 2024 Aug; Vol. 84 (11), pp. 993-1015. Date of Electronic Publication: 2024 Apr 29.
DOI: 10.1002/pros.24721
Abstrakt: Introduction: The 2023 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, themed "Disrupting Prostate Cancer Research: Challenge Accepted," was convened at the University of California, Los Angeles, Luskin Conference Center, in Los Angeles, CA, from June 22 to 25, 2023.
Methods: The 2023 marked the 10th Annual CHPCA Meeting, a discussion-oriented scientific think-tank conference convened annually by the Prostate Cancer Foundation, which centers on innovative and emerging research topics deemed pivotal for advancing critical unmet needs in prostate cancer research and clinical care. The 2023 CHPCA Meeting was attended by 81 academic investigators and included 40 talks across 8 sessions.
Results: The central topic areas covered at the meeting included: targeting transcription factor neo-enhancesomes in cancer, AR as a pro-differentiation and oncogenic transcription factor, why few are cured with androgen deprivation therapy and how to change dogma to cure metastatic prostate cancer without castration, reducing prostate cancer morbidity and mortality with genetics, opportunities for radiation to enhance therapeutic benefit in oligometastatic prostate cancer, novel immunotherapeutic approaches, and the new era of artificial intelligence-driven precision medicine.
Discussion: This article provides an overview of the scientific presentations delivered at the 2023 CHPCA Meeting, such that this knowledge can help in facilitating the advancement of prostate cancer research worldwide.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: